NBRV Insider Trading Activity and SEC Form 4 Filings
NBRV insider trading summary
No open-market insider purchases or sales of Nabriva Therapeutics plc (NBRV) have been reported on SEC Form 4 in the past 12 months.
Latest NBRV insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 2, 2022 | Daniel D Burgess | Director | Sell | $2K (11,341 @ $0.19) |
| Aug 2, 2022 | Stephen W Webster | Director | Sell | $1K (7,826 @ $0.19) |
| Aug 2, 2022 | Colin MD Broom | Director | Sell | $1K (5,339 @ $0.19) |
| Aug 2, 2022 | Mark Corrigan | Director | Sell | $2K (10,297 @ $0.19) |
| Aug 1, 2022 | Charles A Rowland Jr | Director | Sell | $1K (8,496 @ $0.17) |
| Aug 1, 2022 | Carrie L. Bourdow | Director | Sell | $1K (8,540 @ $0.17) |
| Dec 28, 2021 | Theodore R Schroeder | Chief Executive Officer | Buy | $57K (100,000 @ $0.57) |
| Dec 27, 2021 | J. Christopher Naftzger | General Counsel and Corp Sec | Buy | $4K (7,000 @ $0.59) |
| Sep 14, 2021 | Theodore R Schroeder | Chief Executive Officer | Buy | $56K (50,000 @ $1.13) |
| Aug 2, 2021 | Stephen W Webster | Director | Sell | $932 (777 @ $1.20) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.